DTC Risk Disclosures Examined By FDA; Do Minor Risks Swamp Major Ones?
Executive Summary
FDA will evaluate how the presence of minor safety risks in the brief summary of print direct-to-consumer advertisements impacts consumer comprehension of major risks
You may also be interested in...
“Brief Summary” Format Changes: FDA Gets Proof of Principle In First Study
FDA will narrow the focus of subsequent studies examining the "brief summary" of risk information in print drug ads to focus on one medical condition following preliminary results from the first study, which considered three different conditions
“Brief Summary” Format Changes: FDA Gets Proof of Principle In First Study
FDA will narrow the focus of subsequent studies examining the "brief summary" of risk information in print drug ads to focus on one medical condition following preliminary results from the first study, which considered three different conditions
Risk Disclosure In Rx Ad “Brief Summary” To Be Examined By Modified FDA Study
FDA is modifying its upcoming studies of brief summaries in Rx advertising to assess whether changes such as organizing side effects into short- and long-term categories would aid comprehension